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Alzheimer's disease (AD) is associated with impaired clearance of b-amyloid (Ab) from the brain, a process normally facilitated by apolipoprotein E (apoE). ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator-activated receptor gamma and liver X receptors in coordination with retinoid X receptors (RXRs). Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble Ab within hours in an apoE-dependent manner. Ab plaque area was reduced more than 50% within just 72 hours. Furthermore, bexarotene stimulated the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Thus, RXR activation stimulates physiological Ab clearance mechanisms, resulting in the rapid reversal of a broad range of Ab-induced deficits.
T he most common form of Alzheimer's disease (AD) occurs sporadically late in life and is typified by deposition of bamyloid (Ab) within the brain (1) . Individuals with late-onset AD produce Ab peptides at normal levels but have an impaired ability to clear them from the brain (2) . Elevated levels of Ab are associated with perturbations of synaptic function and neural network activity that probably underlie the cognitive deficits in AD (3). Moreover, Ab accumulation leads to its deposition into plaques and is thought to drive a pathologic cascade, which ultimately leads to neuronal death.
The most influential genetic risk factor for sporadic AD is allelic variation in the apolipoprotein E (APOE) gene. Possession of an APOE4 allele markedly increases disease risk (4). ApoE acts normally to scaffold the formation of highdensity lipoprotein (HDL) particles, which promote the proteolytic degradation of soluble forms of Ab (5, 6) .
The expression of apoE is transcriptionally regulated by the ligand-activated nuclear receptors, peroxisome proliferator-activated receptor gamma (PPARg) and liver X receptors (LXRs) (7), which form obligate heterodimers with retinoid X receptors (RXRs). Transcriptional activity is regulated by ligation of either member of the pair (8) . PPARg:RXR and LXR:RXR act in a feed-forward manner to induce the expression of apoE, its lipid transporters ABCA1 and ABCG1, and the nuclear receptors themselves (7) . Agonists of these receptors also act on macrophages and microglia to stimulate their conversion into "alternative" activation states (9) and promote phagocytosis (10) . Chronic administration of LXR and PPARg agonists reduces Ab levels and improves cognitive function in mouse models of AD (10) .
We reasoned that an RXR agonist would enhance normal Ab clearance mechanisms by activating PPARg:RXR and LXR:RXR, inducing apoE expression, facilitating Ab clearance, and promoting microglial phagocytosis. Bexarotene (Targretin) is a highly selective, blood-brain barrierpermeant ( fig. S3A ), RXR agonist approved by the U.S. Food and Drug Administration (FDA) (11) with a favorable safety profile (12) . Treatment of primary microglia or astrocytes with bexarotene stimulated the expression of apoE, ABCA1, and ABCG1 ( fig. S1, A Brain interstitial fluid (ISF) Ab levels were monitored by hippocampal in vivo microdialysis (13) of 2-month-old APPswe/PS1De9 (APP/PS1) mice. Bexarotene rapidly lowered ISF Ab 40 and Ab 42 levels within 6 hours of administration, with a 25% reduction by 24 hours (Fig. 1, A and B). One dose of bexarotene significantly decreased ISF Ab 40 and Ab 42 levels by 25% for more than 70 hours (Fig. 1D) , with a return to baseline by 84 hours. The suppression of ISF Ab was due to increased clearance, as the Ab 40 half-life was reduced from 1.4 to 0.7 hours (Fig. 1C) . Bexarotene reduced murine Ab levels in the C57Bl/6 mice to a similar extent as in APP/PS1 mice; however, it had no effect on Ab levels in apoE-null mice (Fig. 1E) , demonstrating that the enhanced clearance of soluble ISF Ab required apoE. and Ab x-42 were sampled every 2 to 6 hours for 4 days after treatment. (E) Baseline ISF Ab levels of nontransgenic (C57Bl/6) and apoE knockout (KO) mice (2 months) with and without bexarotene treatment. ISF Ab x-40 levels were measured between hours 7 and 12 after treatment; n = 5 mice per group (Student's t test; mean T SEM, *P < 0.05, **P < 0.01, ***P < 0.001). We observed the rapid removal of both diffuse and compact Ab plaques in the cortex and hippocampus of APP/PS1 mice after acute treatment with bexarotene (Fig. 2) . We orally administered bexarotene or vehicle daily to 6-month-old APP/PS1 mice for 3, 7, or 14 days. We observed the progressively enhanced expression of apoE, ABCA1, and ABCG1 and elevated HDL levels in both the hippocampus and cortex of bexarotenetreated mice ( fig. S3, B and C) . There was a sustained 30% reduction in soluble Ab levels throughout the 14-day treatment period (Fig. 2A) . Insoluble Ab levels were reduced by 40% after 72 hours and progressively decreased over the subsequent 14 days (Fig. 2A) . Total (Fig. 2, B and C) and thioflavin-S + Ab plaques (Fig. 2 , E and F) were reduced by~75% after 14 days of bexarotene treatment. Furthermore, we observed abundant Ab-laden microglia after 3 days of bexarotene treatment, suggesting their involvement in the phagocytic removal of Ab deposits (Fig. 2D) .
To assess whether bexarotene could decrease Ab burden in older animals with greater plaque deposition, we treated 11-month APP/PS1 mice with bexarotene for 7 days and found significantly reduced levels of soluble and insoluble Ab 40 and Ab 42 (fig. S4C) , a 50% reduction in plaque number ( fig. S4, D and E) , and a concurrent increase in expression of apoE, the cholesterol transporters, and HDL levels ( fig. S4, A and B) . Thus, the efficacy of acute bexarotene treatment is evident in both early and later stages of pathogenesis in this mouse model.
We also tested the effect of chronic bexarotene treatment (3 months, daily) of APP/PS1 mice starting from 6 months of age. We found elevated levels of apoE, ABCA1, ABCG1, and HDL ( fig.  S5, A and B) . Bexarotene reduced soluble Ab levels by~30%, consistent with its ability to enhance apoE-dependent Ab proteolysis ( fig. S6C) . However, amyloid plaque burden was unchanged ( fig. S5, D to G) .
To evaluate the robustness of the effect of bexarotene, we treated an aggressive model of amyloidosis, the APPPS1-21 mouse (14), which possesses high levels of deposited Ab at 7 to 8 months of age. APPPS1-21 mice treated for 20 days with bexarotene exhibited a reduced level of soluble and insoluble Ab peptides ( fig. S6C) and a 35% decrease in the number of thioflavin S + plaques (fig. S6, D and E) . Bexarotene treatment enhanced the expression of ABCA1, ABCG1, apoE, and its lipidated forms ( fig. S6, A and B) .
There is persuasive evidence that the cognitive and behavioral deficits characteristic of AD arise, in part, from impaired synaptic function due to soluble forms of Ab. Bexarotene treatment rapidly restored cognition and memory, as assessed by contextual fear conditioning in APP/PS1 mice treated for 7 days at both early (6 months) and later (11 months) stages of plaque pathogenesis. Similarly, chronic treatment of 6-month-old APP/PS1 mice for 90 days (analyzed at 9 months of age) (Fig. 3, A to C) showed drug-induced behavioral improvements in the contextual fear conditioning task. Additionally, APP/PS1 mice treated for 90 days and APPPS1-21 mice treated for 20 days exhibited improved hippocampal function after bexarotene treatment, as assessed by Morris water maze performance (Fig. 3, D and  F) , as well as in the contextual fear conditioning assay (Fig. 3E) .
Nest construction is an affiliative, social behavior that becomes progressively impaired in Tg2576 (15) . After just 72 hours of bexarotene treatment, nest construction behavior was restored in Tg2576 mice (Fig. 3G) .
Finally, we explored whether bexarotene could rescue olfactory sensory impairments, (16) , which are highly correlated with Ab deposition in Tg2576 mice (17) . Bexarotene treatment improved odor habituation behavior after 9 days of drug treatment in Tg2576 mice 12 to 14 months of age (Fig. 3H) .
The improved behaviors observed in bexarotene-treated mice suggest global improvements of neural network function. Soluble Ab interferes with synaptic function that subserves higher-order neural network information processing (3). Piriform cortex (PCX) circuit function is critical to odor-guided behaviors, and its disruption is implicated in impaired olfactory perception in both humans with AD and in Tg2576 mice (18) . Therefore, we evaluated odor-evoked PCX local field potentials (LFPs) as a behaviorally relevant synaptic readout of neural circuit status. Odorevoked high-frequency gamma-band oscillations (35 to 75 Hz) and beta-band oscillations (15 to 35 Hz), reflecting local circuit interactions and interregional network activity, respectively, are considered critical for normal olfactory function (18, 19) . Tg2576 mice (12 to 14 months) treated with vehicle exhibited significantly less odorevoked beta-and gamma-band LFP power compared to drug-treated nontransgenic mice (Fig. 4,  A and B) , which was restored by 3 days of bexarotene treatment. Odor habituation after bexarotene treatment was improved in these same mice ( fig. S7, B and C) , indicating a rapid drugdependent normalization of local and regional circuit function in the primary olfactory pathway.
RXR activation stimulates the normal physiological processes through which Ab is cleared from the brain. The dependence of soluble Ab clearance on apoE validates the mechanistic linkage between the principal genetic risk factor for AD and the cognitive impairment that characterizes the disease (5, 6). Bexarotene acts rapidly to facilitate the apoE-dependent clearance of soluble forms of Ab, accounting for the extremely rapid change in ISF Ab metabolism. Bexarotenemediated behavioral improvements were correlated with a reduction in soluble Ab peptide levels of~30%. These observations are consistent with previous observations that learning and memory ).
[Nontransgenic littermates were controls (NonTg), n = 7 to 14 mice per group (Student's t test; mean T SEM, *P < 0.05, **P < 0.01)]. (G) Nest construction was quantified in 12-to 14-month NonTg and Tg2576 mice. Baseline data were obtained on day 0, after daily drug treatment and addition of paper towels in clean cages (two-tailed t test; *P < 0.05, **P < 0.01). (H) Odor habituation behavior in 12-to 14-month Tg2576 mice tested before (baseline) and after 9 days of bexarotene treatment; n = 5 mice per group (two-tailed t test; mean T SEM, **P < 0.01, ***P < 0.001 for Tg2576 baseline versus Tg2576 Bex). (20, 21) or provision of antibodies against Ab (22) . However, the behavioral improvements were poorly correlated with the microglial-mediated removal of insoluble, deposited forms of Ab. The dual actions of the nuclear receptors resulting in the enhanced expression and lipidation of apoE and modulation of the microglial-mediated immune response are consistent with recent genetic association analyses implicating them in the etiology of AD (23) (24) (25) . The ability of bexarotene to rapidly reverse a broad range of deficits suggests that RXR agonists may be of therapeutic utility in the treatment of AD and its antecedent phases. The hippocampus and entorhinal cortex play a pivotal role in spatial learning and memory. The two forebrain regions are highly interconnected via excitatory pathways. Using optogenetic tools, we identified and characterized long-range g-aminobutyric acid-releasing (GABAergic) neurons that provide a bidirectional hippocampal-entorhinal inhibitory connectivity and preferentially target GABAergic interneurons. Activation of long-range GABAergic axons enhances sub-and suprathreshold rhythmic theta activity of postsynaptic neurons in the target areas.
Long-Range-Projecting GABAergic
T he excitatory projections connecting the hippocampus and entorhinal cortex (1) account for the functional interdependence of these two brain regions (2-4). Excitatory neurons in the hippocampus and entorhinal cortex are under control of local g-aminobutyric acid-releasing (GABAergic) interneurons (5, 6) . Some GABAergic neurons also project long distance. For example, long-range-projecting GABAergic cells connect hippocampus with medial septum (7-9) and other extra-hippocampal brain areas (10, 11), suggesting that interregional GABAergic connectivity might be less rare than was previously assumed (12) .
To test for the presence of hippocampal GABAergic neurons projecting to the medial enthorinal cortex (MEC), we injected the retrograde tracer fluorogold (FG) into the MEC of wild-type mice ( fig. S1 ). In addition to the expected labeling of numerous excitatory cells, we found FG + neurons in stratum oriens and stratum radiatum of CA1 and in the hilus of the dentate gyrus (DG), indicating retrogradely labeled GABAergic cells. We detected FG-labeled cells coexpressing somatostatin (SOM) in stratum oriens of CA1 (23 cells, nine mice) and also in the hilus of the DG (14 cells, nine mice) (Fig. 1, A and B) . ) or vehicle (H 2 O) for 3 days after implantation of electrodes into PCX. PCX LFPs in response to the odor ethyl valerate in an awake nontransgenic, bexarotene-treated mouse. (A) Fifteento 35-Hz beta-and 35-to 75-Hz gammaband power traces (second-order band pass). (B) PCX odor-evoked response magnitudes (2 s odor/2 s pre-odor) (n = 5 mice per group, four odor presentations per mouse; *P < 0.05, **P < 0.01, ***P < 0.001, mean T SEM, two-tailed t tests of mean odor-evoked magnitudes within LFP bins). ns, not significant. 
